140 related articles for article (PubMed ID: 34890753)
1. Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy.
Chen H; Poon I; Atenafu EG; Badellino S; Biswas T; Dagan R; Erler D; Foote M; Redmond KJ; Ricardi U; Sahgal A; Louie AV
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):892-901. PubMed ID: 34890753
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy for metastatic lung metastases.
Kimura T; Fujiwara T; Kameoka T; Adachi Y; Kariya S
Jpn J Radiol; 2022 Oct; 40(10):995-1005. PubMed ID: 36097233
[TBL] [Abstract][Full Text] [Related]
5. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.
Piroth MD; Krug D; Feyer P; Baumann R; Combs S; Duma MN; Dunst J; Fastner G; Fietkau R; Guckenberger M; Haase W; Harms W; Hehr T; Sedlmayer F; Souchon R; Strnad V; Budach W
Strahlenther Onkol; 2022 Jul; 198(7):601-611. PubMed ID: 35527272
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
7. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.
Kroese TE; Jorritsma NKN; van Laarhoven HWM; Verhoeven RHA; Mook S; Haj Mohammad N; Ruurda JP; van Rossum PSN; van Hillegersberg R
Clin Transl Radiat Oncol; 2022 Nov; 37():109-115. PubMed ID: 36186924
[TBL] [Abstract][Full Text] [Related]
9. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
10. Repeat stereotactic body radiotherapy for oligometastatic disease.
Willmann J; Adilovic S; Vlaskou Badra E; Christ SM; Ahmadsei M; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2023 Jul; 184():109671. PubMed ID: 37059336
[TBL] [Abstract][Full Text] [Related]
11. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
12. Outcomes for oligometastatic head and neck cancer treated with stereotactic body radiotherapy: Results from an international multi-institutional consortium.
Id Said B; Mutsaers A; Chen H; Husain ZA; Biswas T; Dagan R; Erler D; Foote M; Louie AV; Redmond K; Ricardi U; Sahgal A; Poon I
Head Neck; 2023 Oct; 45(10):2627-2637. PubMed ID: 37602655
[TBL] [Abstract][Full Text] [Related]
13. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
14. Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer.
Kroese TE; Buijs GS; Burger MDL; Ruurda JP; Mook S; Brosens LAA; van Rossum PSN; van Hillegersberg R
Ann Surg Oncol; 2022 Aug; 29(8):4848-4857. PubMed ID: 35381938
[TBL] [Abstract][Full Text] [Related]
15. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
[TBL] [Abstract][Full Text] [Related]
16. Distant Metastasis Velocity as a Novel Prognostic Score for Overall Survival After Disease Progression Following Stereotactic Body Radiation Therapy for Oligometastatic Disease.
Willmann J; Vlaskou Badra E; Adilovic S; Christ SM; Ahmadsei M; Mayinger M; Tanadini-Lang S; Guckenberger M; Andratschke N
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):871-882. PubMed ID: 35718253
[TBL] [Abstract][Full Text] [Related]
17. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
19. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
20. Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease.
Rieber J; Abbassi-Senger N; Adebahr S; Andratschke N; Blanck O; Duma M; Eble MJ; Ernst I; Flentje M; Gerum S; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl H; Klass ND; Krempien R; Lohaus F; Lohr F; Petersen C; Schrade E; Streblow J; Uhlmann L; Wittig A; Sterzing F; Guckenberger M
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):511-520. PubMed ID: 27843031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]